Aims/hypothesis GIP(6-30)Cex-K 4 0 [Pal] has been characterised as a fatty-acid-derived gastric inhibitory polypeptide (GIP) inhibitor that can induce pancreatic beta cell rest by diminishing the incretin effect. We investigated its therapeutic efficacy with and without the glucagon-like peptide-1 (GLP-1) beta cell cytotropic agent liraglutide. Methods The therapeutic efficacy of GIP(6-30)Cex-K 40 [Pal] alone, and in combination with liraglutide, was determined in C57BL/KsJ db/db mice using a sequential 12 h administration schedule.
Introduction
Type 2 diabetes is characterised by pancreatic beta cell destruction, which results in an increased insulin-secretory demand on remaining beta cells [1, 2] . This results in further Electronic supplementary material The online version of this article (doi:10.1007/s00125-015-3653-1) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
progressive loss of beta cell mass and function, ultimately leading to exogenous insulin becoming the mainstay therapy [3] . Conventional beta cell stimulatory glucose-lowering drugs, such as sulfonylureas, induce a reduction in beta cell mass over time [4] . Thus, the beneficial effects of extended periods of beta cell rest have been considered as a suitable approach to preserve long-term beta cell function and improve overall enduring glycaemic control [1] .
In this context, inhibition of gastric inhibitory polypeptide (GIP) receptor signalling has been shown to improve metabolic control and glycaemic status in animal models of obesity-related diabetes [5 -7 ] . Nonetheless, the principally recognised biological function of GIP is as an incretin hormone that potentiates glucose-induced insulin secretion [8] . Therefore, a likely aspect of the beneficial effects of GIP receptor blockade could be related to the induction of pancreatic beta cell rest [9, 10] . Although GIP receptor inhibitors have already been described [10] [11] [12] [13] , some doubt still exists regarding their capacity to detrimentally inhibit the naturally occurring incretin effect following feeding in humans [5] . Unlike conventional sulfonylureas glucagon-like peptide-1 (GLP-1) stimulates insulin secretion in a glucose-dependent fashion and this helps to preserve beta cell mass and function [14] . It follows that co-administration of GLP-1 coupled with appropriate periods of beta cell rest induced by administration of a GIP receptor inhibitor could represent a useful therapeutic approach for type 2 diabetes. Consequently, we have attempted to replicate this scenario, through staggered administration of GIP(6-30)Cex-K 40 [Pal] and the clinically approved GLP-1 mimetic liraglutide. GIP Cex-K 40 [Pal] is a novel effective GIP inhibitor based on GIP that is known to bind, but not activate, the GIP receptor [15] .
Following in vitro and in vivo characterisation of GIP(6-30)Cex-K 40 [Pal], we determined the most appropriate doses of GIP Cex-K 40 [Pal] and liraglutide that would allow separate once-daily administration of each, with little overlap of biological actions. This facilitated a twice-daily (at 08:00 and 20:00 hours) dosing regimen in C57BL/KsJ db/db mice, where beta cells would be stimulated for 8-12 h by liraglutide and then be rested for the remaining 8-12 h of the day through subsequent GIP(6-30)Cex-K
40
[Pal] administration. Notably, akin to the human setting, db/db mice exhibit a gradual agedependent loss of beta cell mass, which culminates in islet degeneration, hyperglycaemia and overt diabetes [16] . Here we demonstrate the positive metabolic effects of combined GIP(6-30)Cex-K
[Pal] and liraglutide therapy on circulating glucose concentrations, glucose tolerance and insulin sensitivity. These effects were particularly apparent when GIP(6-30)Cex-K 40 [Pal] was administered during the light cycle, coupled with liraglutide injection during the dark cycle.
Methods
Peptides Peptides were purchased from GL Biochem (Shanghai, China). GIP(6-30)Cex-K
40
[Pal] was synthesised on a native GIP backbone with subsequent C-terminal extension (Cex) of the nine C-terminal amino acid residues of exendin(1-39). A C-16 fatty acid moiety (palmitate [Pal] ) was attached to an additional Lys 40 residue via a γ-glutamyl spacer. Peptides were characterised in-house using matrix-assisted laser desorption/ionisation-time of flight (MALDI-ToF) MS, as described previously [13] . The structures of native GIP and GIP In vitro cAMP production Chinese Hamster Lung (CHL) cells transfected with the human GIP receptor were used [13] . This cell line was a gift from. B. Thorens (University of Lausanne, Switzerland [13] ). For experimental conditions please see ESM Methods for further details. cAMP generation was measured using a Parameter cAMP assay (R&D Systems, Abingdon, UK) according to the manufacturer's instructions.
In vitro insulin release studies Clonal BRIN-BD11 cells were used, the characteristics of which have been described elsewhere [17] . This cell line was established in-house after electrofusion of RINm5F cells with New England Deaconess Hospital rat pancreatic islet cells [17] . For experimental conditions please see ESM Methods for further details. Insulin was measured by radioimmunoassay [18] .
Animals Acute and persistent dose-dependency studies were carried out in male NIH Swiss mice. Longer-term experiments were conducted with male C57BL/KsJ db/db mice. For further details of mouse age and maintenance please see ESM Methods. [Pal] was given at a dose of 2.5 nmol/kg and liraglutide at 0.25 nmol/kg. Energy intake, body weight, non-fasting plasma glucose and plasma insulin concentrations were measured 6 days before the study and at 2-5 day intervals during the study. On day 28, glucose tolerance (18 mmol/ kg, oral and i.p.) and insulin sensitivity (15 U/kg) tests were carried out in separate groups of fasted (18 h) and non-fasted mice, respectively. These tests and other blood collections were performed at 08:00 hours, and daily injections were withheld until after blood collection. After the animals were killed, pancreatic tissue was collected for measurement of insulin following extraction using acid ethanol (5 ml/g), as described previously [19] . For details of further terminal analyses please see ESM Methods.
Acute in vivo studies
Real-time RT-PCR Adipose tissue mRNA extraction and cDNA conversion were carried out using Qiazol lysis reagent (Qiagen, Manchester, UK) and superscript II reverse transcriptase -RNase H kit (Invitrogen, Paisley, UK) following the manufacturer's instructions. For PCR reaction mixture and conditions please see ESM Methods for further details.
Biochemical analysis From the cut tip of the tail vein of conscious mice, blood samples were collected into fluoride/ heparin microcentrifuge tubes (Sarstedt, Numbrecht, Germany) at the times indicated in the Figures. Samples were immediately centrifuged (Beckman microcentrifuge; Beckman Instruments, High Wycombe, UK) for 30 s at 13,000 g and resulting plasma was stored at −20°C until analysis. Plasma and pancreatic insulin levels were determined by an insulin radioimmunoassay as described previously [18] . Plasma glucose was assayed by an automated glucose oxidase procedure using a Beckman Glucose Analyser II (Beckman Instruments, Galway, Ireland).
Statistical analysis
For gene expression studies (Table 2 ) and pancreatic insulin content (Fig. 4d ) all samples were numbered and blinded. For acute and subchronic metabolic tests, there was no blinding. All results are expressed as means± SEM and data were compared using unpaired t test and oneway ANOVA, followed by the Student-Newman-Keuls post hoc test. AUCs were calculated using the trapezoidal rule with baseline subtraction (PRISM 5; GraphPad Software, San Diego, CA, USA). Statistical significance between groups of data was considered if p<0.05.
Results
In vitro cAMP production and insulin secretion Native GIP evoked a concentration-dependent increase in cAMP production in GIP receptor-transfected cells (Fig. 1a) . In contrast, GIP(6-30)Cex-K
40
[Pal] did not affect basal cAMP generation (Fig. 1a) . However, when incubated with stimulatory native GIP (10 (Table 1) . However, when administered at a dose of 0.25 nmol/kg, the glucose-lowering and insulin-secretory actions of GIP were still apparent (Table 1) . Interestingly, when injected 8 h previously, liraglutide evoked prominent and significant ( p<0.05 to p<0.001) glucoselowering and insulinotropic actions at all doses examined (Table 1 ). In addition, when administered 12 h before the glucose challenge all doses of liraglutide, barring 0.25 nmol/ kg, were effective in lowering plasma glucose levels ( p<0.001) and elevating insulin concentrations ( p<0.01 to p < 0.001) compared with saline control (Table 1) . With regards to GIP(6-30)Cex-K
[Pal] administered 12 h before the glucose challenge, only doses of 25 and 12.5 nmol/kg were effective ( p<0.001) in annulling the biological action of native GIP (Table 1) . When injected 24 h beforehand, only the highest dose of GIP(6-30)Cex-K
[Pal] tested, 25 nmol/ kg, was effective in thwarting the beneficial glucose-lowering and insulin-releasing actions of GIP (Table 1) . Liraglutide induced clear ( p<0.05 to p<0.001) glucose-lowering effects at doses of 25, 12.5 and 2.5 nmol/kg, when administered 24 h previously (Table 1) . However, only doses of 25 and 12.5 nmol/kg liraglutide had significant ( p<0.001) overall beneficial insulin-secretory effects when injected 24 h previously (Table 1) .
Subchronic effects of GIP(6-30)Cex-K
[Pal] and liraglutide, alone and in combination, on body weight, energy intake, plasma glucose and insulin in db/db mice Twice-daily injection of GIP(6-30)Cex-K 40 [Pal] or liraglutide, alone and in combination, significantly ( p <0.05 to p <0.01) lowered body-weight gain at various observation points over the treatment period (Fig. 2a) . Indeed, on day 28 body-weight gain was significantly ( p<0.05 to p<0.01) reduced in all treatment groups, barring liraglutide in the morning and GIP(6-30)Cex-K
[Pal] in the evening (Fig. 2a) . Percentage body fat was significantly reduced in all treatment groups by day 28 (Fig. 2b) . All treatment regimens, barring twice-daily injection of GIP(6-30)Cex-K
[Pal], significantly ( p<0.05 to p<0.01) reduced energy intake on at least one observation day (Fig. 2c) . Non-fasting plasma glucose levels were significantly ( p<0.05 to p<0.001) reduced in all treatment groups on days 26 and 28, except in those mice given liraglutide in the (Fig. 2d ). Mice treated with GIP(6-30)Cex-K 40 [Pal] in the morning (08:00 hours) and liraglutide in the evening (20:00 hours) had reduced ( p<0.05 to p<0.001) circulating glucose levels from day 8 onwards (Fig. 2d) . Non-fasting plasma insulin concentrations were also significantly lowered ( p<0.05 to p<0.001) in this group of mice at all but one observation point (Fig. 2e) . All other treatment groups had reduced ( p<0.05) insulin concentrations on only one or two of the nine observation days during the treatment period (Fig. 2e) .
[Pal] and liraglutide, alone and in combination, on glucose tolerance and plasma insulin responses in db/db mice Glucose levels were significantly ( p<0.05 to p<0.01) reduced at 30, 60 and 105 min post i.p. injection of glucose in mice treated with GIP(6-30)Cex-K 40 [Pal] at 08:00 hours combined with liraglutide at 20:00 hours (Fig. 3a) . This was accompanied by a significantly ( p<0.001) reduced overall glycaemic excursion (Fig. 3a inset) . Notably, none of the other treatment regimens reduced the overall glycaemic excursion (Fig. 3a inset) . Indeed, the GIP(6-30)Cex-K
[Pal] morning and liraglutide evening group had significantly ( p<0.05 to p<0.01) decreased overall AUC values compared with all other treatment groups (Fig. 3a) .
Corresponding glucose-induced insulin concentrations revealed a similar situation, with GIP(6-30)Cex-K
[Pal] treatment in the morning and liraglutide treatment in the evening clearly being the most effective treatment modality (Fig. 3b) . Moreover, AUC measures were significantly ( p<0.05 to p<0.01) elevated in these mice when compared with db/db mice treated twice daily with saline control or GIP(6-30)Cex-K
[Pal] and those treated with liraglutide in the morning and GIP(6-30)Cex-K 40 [Pal] in the evening (Fig. 3b) . Similar observations were also made during an oral glucose challenge at the end of the study (Fig. 3c, d ). As such, GIP(6-30)Cex-K 40 [Pal] treatment in the morning coupled with liraglutide administration in the evening significantly ( p<0.05 to p<0.01) decreased overall glucose levels compared with controls and all other mice that received liraglutide therapy (Fig. 3c ). An identical scenario was observed in terms of overall oral glucose-stimulated insulin concentrations (Fig. 3d) .
Subchronic effects of GIP(6-30)Cex-K 40
[Pal] and liraglutide, alone and in combination, on insulin sensitivity, HOMA-IR and pancreatic insulin content in db/db mice At the end of the study, only those mice that were administered GIP(6-30)Cex-K 40 [Pal] in the morning together with liraglutide in the *p<0.05, **p<0.01 and ***p<0.001 compared with respective control evening had significantly ( p<0.05) reduced individual plasma glucose levels at 30 and 60 min following exogenous insulin injection (Fig. 4a) . However, the overall glucoselowering response to insulin was significantly ( p<0.05 to p<0.001) augmented in all treatment groups, except those mice given liraglutide in the morning and GIP(6-30)Cex-K
40
[Pal] in the evening, when compared with saline controls (Fig. 4b) . HOMA-IR was also significantly ( p <0.05 to p<0.001) decreased in all treatment groups when compared with saline control (Fig. 4c) . In addition, all groups, barring those given liraglutide in the morning and GIP(6-30)Cex-K 40 [Pal] in the evening, had significantly ( p < 0.05 to p<0.001) reduced pancreatic insulin content at the end of the study (Fig. 4d) .
Subchronic effects of GIP(6-30)Cex-K 40
[Pal] and liraglutide, alone and in combination, on adipose tissue gene expression in db/db mice Twice-daily administration of GIP(6-30)Cex-K 40 [Pal] significantly ( p<0.05 to p<0.01) reduced Gipr, Fatp, Lpl and Acc-1 (also known as Acc1) mRNA expression in db/db mice when compared with administration of saline control (Table 2) . Similar twice-daily treatment with liraglutide reduced mRNA expression of Gipr ( p < 0.001), Glp1r ( p < 0.01), Gcgr ( p < 0.05), Lpl ( p < 0.001), Dgat1 ( p<0.001), Acc-1 ( p<0.01) and Hsl ( p<0.05) compared with the expression in control db/db mice (Table 2) . However, administration of GIP(6-30)Cex-K
40
[Pal] at 08:00 hours followed by liraglutide at 20:00 hours markedly reduced the transcription of Gipr ( p<0.05), Gcgr ( p<0.001), Insr ( p <0.05), Lpl ( p<0.01) and Fatp ( p<0.01), while increasing ( p<0.01) transcription of Hsl ( Table 2 ). The reciprocal treatment regimen of liraglutide at 08:00 hours followed by GIP(6-30)Cex-K
[Pal] at 20:00 hours had nominal effects on adipocyte gene expression, with significantly decreased ( p<0.01) Glp1r mRNA expression and increased ( p<0.05) Insr expression ( Table 2) . None of the treatment regimens affected expression of Glut4 (Slc2a4).
Discussion
Agents that directly induce pancreatic beta cell rest may also have additional beneficial extrapancreatic actions on glucose metabolism beyond their direct inhibitory effects on beta cells [1], which is undoubtedly the case for GIP(6-30)Cex-K
40
[Pal] [5] . However, uncertainty remains regarding the therapeutic promise of compromised GIP receptor signalling in man. We have evaluated the therapeutic efficacy of combined, but separated by 12 h, daily administration of GIP(6-30)Cex-K 40 [Pal] and liraglutide in C57/BL6J db/db mice. We developed GIP(6-30)Cex-K 40 [Pal] as a novel GIP inhibitor. This peptide analogue is not susceptible to dipeptidyl peptidase-4 degradation because it lacks the N-terminal amino acids Tyr 1 -Ala 2 . Moreover, addition of the nine-amino-acid C-terminal extension of exendin1-39 (Cex), together with lipidation at Lys 40 , aids stability, reduces clearance and enhances in vivo activity [20] [21] [22] . GIP(6-30)Cex-K 40 [Pal] did not stimulate cAMP production or insulin secretion in vitro. Importantly, GIP(6-30)Cex-K 40 [Pal] dose-dependently compromised GIPinduced elevation of cellular cAMP production and insulin secretion. This indicates that GIP(6-30)Cex-K 40 [Pal] retains GIP-receptor-binding affinity and actively competes with the native peptide [15] . GIP(6-30)Cex-K 40 [Pal] also inhibited the glucose-lowering and insulinsecretory effects of native GIP in normal mice.
To discover the most appropriate treatment regimen for subchronic evaluation in db/db mice, we embarked on a series of acute dose-and time-dependent studies in normal mice pertaining to the biological actions of GIP (6- [Pal] should be employed at a dose of 2.5 nmol/kg, and liraglutide at 0.25 nmol/kg, in order to achieve a biological action profile greater than 8 h but less than 12 h. Accordingly, these respective doses were employed for the subsequent 28 day subchronic study in db/db mice. In accordance with the established satiating effect of GLP-1 receptor activation [14] , all db/db mice treated with liraglutide for 28 days exhibited marked decreases in food intake. In addition, there were notable reductions in bodyweight gain in all mice, independent of energy intake. Thus, as noted previously, reduction in body-weight gain with GIP receptor blockade is directly related to the extent of GIP receptor annulment induced [6] , regardless of feeding behaviour [5] . This points towards a possible effect on adipose tissue leading to increased energy dissipation [5] . Consistent with this, there was a clear decrease in the percentage of body-fat mass with all treatment regimens. Reduced adiposity would be expected to indirectly improve the action of insulin, and all treatment groups had improved HOMA-IR values. However, detailed assessment of metabolic rate and locomotor activity would be useful to demonstrate increased energy expenditure, as observed previously in mice with diminished GIP activity [6, 14] . Nonetheless, all mice, barring those given liraglutide at 08:00 hours and GIP(6-30)Cex-K 40 [Pal] at 20:00 hours, exhibited significantly improved hypoglycaemic responses to exogenous insulin. Indeed, this same group of db/db mice had unchanged pancreatic insulin stores, whereas all other treatment groups had markedly reduced stores, indicative of reduced insulin demand.
Of the treatment modalities employed, the most effective was clearly GIP(6-30)Cex-K 40 [Pal] administered at 08:00 hours coupled with liraglutide treatment at 20:00 hours. Thus, beta cell rest was induced during the light phase when mice were less likely to consume food, with beta cell stimulation during the more active dark phase [23] . For example, this group of mice had markedly reduced glucose concentrations in the non-fasting state, and during glucose tolerance tests, when compared with all other groups. In addition, circulating insulin levels were distinctly lower, insulin sensitivity and HOMA-IR were improved and glucose-stimulated insulin concentrations elevated. This is characteristic of the beneficial effects associated with extended periods of beta cell rest [24] . As such, prolonged periods of rest would clearly allow chronically overstimulated beta cells to replenish the immediately secretable insulin granule pool [25] . Such actions, together with the positive effects of GLP-1 receptor activation on beta cell stimulus-secretion coupling, survival and growth [14] , are potential mediators of the observed beneficial effects.
Other factors known to occur during extended periods of beta cell rest, such as enhanced activity of beta cell glucokinase [26] or improved hepatic glucose handling [27] , may also contribute to the observed effects. The enhancement of insulin sensitivity is also likely to reflect upregulation of insulin receptors consequent to alleviation of hyperinsulinaemia [28] . Analysis of the effects of the treatments on adipose tissue gene expression also indicates substantial effects at the molecular level. Twice-daily administration of GIP(6-30)Cex-K
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